As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.
bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.
bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.
DiagnoSwiss and bioMérieux announce that they have signed an exclusive license agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics
Monthey (Switzerland) – bioMérieux and DiagnoSwiss announced today that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of its new microelisa assay for the detection of hepatitis B surface antigen. Hepanostika® HBsAg Ultra is officially presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) currently being held from July 2-6 in Athens, Greece.
Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.
A world leader in the field of in vitro diagnostics, bioMérieux SA announces the launch of a new product for rapid, reliable identification of Methicillin-Resistant Staphylococcus aureus, a common cause of nosocomial infections.
Roche Diagnostics and bioMérieux announce that Roche has granted non exclusive rights for cardiac markers NT-proBNP to bioMérieux
Roche Diagnostics and bioMérieux announced today, that bioMérieux has been granted a nonexclusive license agreement under the patent rights of Roche Diagnostics relating to the development, manufacturing and marketing of immunoassays that detect a key cardiac marker of congestive heart failure and acute coronary syndrome.
Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics
The agreement includes an option for bioMérieux to use Affymetrix GeneChip® technology in other cancer areas.